Manreet Kaur Kanwar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manreet Kaur Kanwar has a total of 760 co-authors. Here are the top co-authors by number of shared publications:
Srinivas Murali
Cardiovascular Institute, Allegheny Health Network
16 shared publicationsShashank S. Sinha
14 shared publicationsJaime Hernandez-Montfort
Baylor Scott and White Health, Advanced Heart Failure Program Clinic, Temple, Texas, USA
13 shared publications- Navin Kumar Kapur
Tufts Medical Center
13 shared publications Amresh Raina
Cardiovascular Institute at Alleghany Health Network, Pittsburgh, Pennsylvania, USA
12 shared publications- Arthur Reshad Garan
Beth Israel Deaconess Medical Center
12 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Waitlist outcomes of multiorgan heart transplant candidates
- 27 October 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Open AccessWaitlist outcomes of multiorgan heart transplant candidates
- Open Access
- 29 September 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Building Interventional Heart Failure: The Path to a Recognized Discipline
- 29 September 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Open AccessBuilding Interventional Heart Failure: The Path to a Recognized Discipline
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Arterial Pulsatility Index in Acute Myocardial Infarction‐Related Cardiogenic Shock: Clinical Characteristics and Association With Outcomes
Background: The arterial pulsatility index (API) is a promising hemodynamic surrogate of left ventricular function, but its prognostic value in acute myocardial infarction‐related cardiogenic shock (AMI‐CS) remains unclear. This study evaluated associations between API, a modified API (mAPI), clinical characteristics, and in‐hospital outcomes in AMI‐CS. Methods: Patients with AMI‐CS in the multicenter CSWG (Cardiogenic Shock Working Group) registry with available API or mAPI were analyzed. API was calculated as systemic arterial pulse pressure/pulmonary capillary wedge pressure; mAPI used pulmonary artery diastolic pressure instead of wedge pressure. Logistic/linear regression, spline modeling, and receiver operating characteristic curve analysis were used to assess associations with clinical characteristics and in‐hospital outcomes. Results: Among 487 patients with AMI‐CS, median API and mAPI were 2.1 (interquartile range [IQR], 1.3–3.2; n=139) and 1.7 (IQR, 1.0–2.8; n=487), respectively. API strongly correlated with mAPI (Pearson r =0.75, P P =0.051) or mAPI (41.2% versus 59.1%, P P =0.006; and 44.1% versus 32.2%; OR, 1.657 [95% CI, 1.147–2.402]; P =0.007). Every 0.5‐unit decrease in API or mAPI was associated with a 2.4% (β=0.024 [95% CI, 0.002–0.045]; P =0.030) and 1.4% (β=0.014 [95% CI, 0.002–0.026]; P =0.022) increase in in‐hospital mortality. Conclusions: In AMI‐CS, lower API and mAPI were associated with increased mortality. API and mAPI may facilitate early risk assessment and guide tailored treatment decisions in AMI‐CS.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Open AccessArterial Pulsatility Index in Acute Myocardial Infarction‐Related Cardiogenic Shock: Clinical Characteristics and Association With Outcomes
Background: The arterial pulsatility index (API) is a promising hemodynamic surrogate of left ventricular function, but its prognostic value in acute myocardial infarction‐related cardiogenic shock (AMI‐CS) remains unclear. This study evaluated associations between API, a modified API (mAPI), clinical characteristics, and in‐hospital outcomes in AMI‐CS. Methods: Patients with AMI‐CS in the multicenter CSWG (Cardiogenic Shock Working Group) registry with available API or mAPI were analyzed. API was calculated as systemic arterial pulse pressure/pulmonary capillary wedge pressure; mAPI used pulmonary artery diastolic pressure instead of wedge pressure. Logistic/linear regression, spline modeling, and receiver operating characteristic curve analysis were used to assess associations with clinical characteristics and in‐hospital outcomes. Results: Among 487 patients with AMI‐CS, median API and mAPI were 2.1 (interquartile range [IQR], 1.3–3.2; n=139) and 1.7 (IQR, 1.0–2.8; n=487), respectively. API strongly correlated with mAPI (Pearson r =0.75, P P =0.051) or mAPI (41.2% versus 59.1%, P P =0.006; and 44.1% versus 32.2%; OR, 1.657 [95% CI, 1.147–2.402]; P =0.007). Every 0.5‐unit decrease in API or mAPI was associated with a 2.4% (β=0.024 [95% CI, 0.002–0.045]; P =0.030) and 1.4% (β=0.014 [95% CI, 0.002–0.026]; P =0.022) increase in in‐hospital mortality. Conclusions: In AMI‐CS, lower API and mAPI were associated with increased mortality. API and mAPI may facilitate early risk assessment and guide tailored treatment decisions in AMI‐CS.
- 24 July 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study
In obese patients receiving durable left ventricular assist devices (LVADs), obesity increases device-related morbidity and may limit access to heart transplantation, while the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains undefined. We performed a retrospective propensity-matched cohort study using the TriNetX US Collaborative Network of adults with obesity who underwent durable LVAD implantation in the United States between 2016 and 2024. Patients with documented GLP-1 RA exposure before implantation were matched 1:1 to nonusers on demographics and baseline comorbidities. The primary outcome was all-cause mortality; secondary outcomes included driveline infection, device malfunction, sepsis, bleeding complications, transplant listing, and heart transplantation at 1 and 3 years. Among 527 obese LVAD recipients, 231 had documented preimplant exposure. After matching, 141 patients were analyzed in each group. At 1 year, exposed patients had a lower hazard of driveline infection. At 3 years, nonusers had higher all-cause mortality, whereas exposed patients had higher rates of transplant listing and heart transplantation. Documented preimplant GLP-1 RA exposure was associated with improved longer-term survival, fewer driveline infections, and greater progression to transplant-related outcomes. These findings are observational and hypothesis-generating but support prospective evaluation in selected LVAD recipients.
- 24 July 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study
In obese patients receiving durable left ventricular assist devices (LVADs), obesity increases device-related morbidity and may limit access to heart transplantation, while the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains undefined. We performed a retrospective propensity-matched cohort study using the TriNetX US Collaborative Network of adults with obesity who underwent durable LVAD implantation in the United States between 2016 and 2024. Patients with documented GLP-1 RA exposure before implantation were matched 1:1 to nonusers on demographics and baseline comorbidities. The primary outcome was all-cause mortality; secondary outcomes included driveline infection, device malfunction, sepsis, bleeding complications, transplant listing, and heart transplantation at 1 and 3 years. Among 527 obese LVAD recipients, 231 had documented preimplant exposure. After matching, 141 patients were analyzed in each group. At 1 year, exposed patients had a lower hazard of driveline infection. At 3 years, nonusers had higher all-cause mortality, whereas exposed patients had higher rates of transplant listing and heart transplantation. Documented preimplant GLP-1 RA exposure was associated with improved longer-term survival, fewer driveline infections, and greater progression to transplant-related outcomes. These findings are observational and hypothesis-generating but support prospective evaluation in selected LVAD recipients.
- 30 June 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (10) , 103183
Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation
- 30 June 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (10) , 103183
Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e013838
Compensating Heart Failure Cardiologists: Is the RVU Model the Right Model?
Physician compensation models in the United States are diverse, shaped by practice settings, specialties, and institutional factors. A notable shift in academic medical centers has been the transition from salary-based compensation to relative value unit (RVU)-based models. While this shift may align compensation with clinical productivity and facilitate budgetary planning, it has profound implications for physician satisfaction, burnout, and clinical practice, particularly in primarily cognitive/nonprocedural based specialties like advanced heart failure (AHF). This article explores the benefits and drawbacks of the RVU model, with a focus on its application in AHF care. The RVU system, designed to measure physician work, practice expenses, and malpractice risk, is associated with efficiency incentives but also risks prioritizing quantity over quality, especially in multidisciplinary fields like AHF. Patients with AHF often have multiple comorbidities requiring extensive management and care coordination across multiple subspecialties, outside of the work effort captured by a clinic visit. The RVU model may undervalue the comprehensive, longitudinal care AHF specialists provide. Through a detailed examination of inpatient and outpatient AHF management, we argue that the RVU model may inadequately capture the full scope of AHF care, which may contribute to systemic challenges, physician burnout, and a decline in interest in AHF subspecialty training. Hence, we call for a reconsideration of AHF physician compensation and productivity measurement that more accurately reflects the full breadth of comprehensive AHF care.
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e013838
Compensating Heart Failure Cardiologists: Is the RVU Model the Right Model?
Physician compensation models in the United States are diverse, shaped by practice settings, specialties, and institutional factors. A notable shift in academic medical centers has been the transition from salary-based compensation to relative value unit (RVU)-based models. While this shift may align compensation with clinical productivity and facilitate budgetary planning, it has profound implications for physician satisfaction, burnout, and clinical practice, particularly in primarily cognitive/nonprocedural based specialties like advanced heart failure (AHF). This article explores the benefits and drawbacks of the RVU model, with a focus on its application in AHF care. The RVU system, designed to measure physician work, practice expenses, and malpractice risk, is associated with efficiency incentives but also risks prioritizing quantity over quality, especially in multidisciplinary fields like AHF. Patients with AHF often have multiple comorbidities requiring extensive management and care coordination across multiple subspecialties, outside of the work effort captured by a clinic visit. The RVU model may undervalue the comprehensive, longitudinal care AHF specialists provide. Through a detailed examination of inpatient and outpatient AHF management, we argue that the RVU model may inadequately capture the full scope of AHF care, which may contribute to systemic challenges, physician burnout, and a decline in interest in AHF subspecialty training. Hence, we call for a reconsideration of AHF physician compensation and productivity measurement that more accurately reflects the full breadth of comprehensive AHF care.
- Open Access
- 15 May 2026
- Published by Association for Computing Machinery (ACM) in ACM Transactions on Computing for Healthcare
It’s Not Just for Trust: Designing for Emerging Uses of Explainable AI in Clinical Decision-Making
Explainable AI (XAI) is often viewed as a mechanism to promote the transparency and interpretability of AI recommendations in high-stakes domains, such as healthcare. This has led many studies to focus on designing and evaluating XAI to foster trust, calibrate reliance, enable algorithmic recourse, and support model understanding. However, this limited design scope restricts our understanding of how XAI can be used more broadly to support critical tasks in complex workflows, such as facilitating shared decision-making and supporting communication between stakeholders. Our work aims to address these critical gaps in the design for and understanding of XAI's emerging uses by iteratively prototyping XAI designs for an AI-powered clinical decision-support system with clinical stakeholders. We then created a high-fidelity prototype from those iterative sessions and used it as a design probe to uncover four emerging uses of XAI: collaboratively exploring treatment options, identifying and reflecting on treatment plans, communicating with stakeholders, and supporting health education. We reflect on the implications of designing XAI for emerging uses in healthcare.
- 15 May 2026
- Published by Association for Computing Machinery (ACM) in ACM Transactions on Computing for Healthcare
Open AccessIt’s Not Just for Trust: Designing for Emerging Uses of Explainable AI in Clinical Decision-Making
Explainable AI (XAI) is often viewed as a mechanism to promote the transparency and interpretability of AI recommendations in high-stakes domains, such as healthcare. This has led many studies to focus on designing and evaluating XAI to foster trust, calibrate reliance, enable algorithmic recourse, and support model understanding. However, this limited design scope restricts our understanding of how XAI can be used more broadly to support critical tasks in complex workflows, such as facilitating shared decision-making and supporting communication between stakeholders. Our work aims to address these critical gaps in the design for and understanding of XAI's emerging uses by iteratively prototyping XAI designs for an AI-powered clinical decision-support system with clinical stakeholders. We then created a high-fidelity prototype from those iterative sessions and used it as a design probe to uncover four emerging uses of XAI: collaboratively exploring treatment options, identifying and reflecting on treatment plans, communicating with stakeholders, and supporting health education. We reflect on the implications of designing XAI for emerging uses in healthcare.
- Open Access
- 10 May 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (9) , 103159
Survival Outcomes in Middle-Aged and Older Patients With Advanced Heart Failure
- 10 May 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (9) , 103159
Open AccessSurvival Outcomes in Middle-Aged and Older Patients With Advanced Heart Failure